 |
 |
Audience: Neuropsychiatric healthcare professionals
FDA and Lilly notified healthcare professionals of revision to the WARNINGS section of labeling, describing the increased risk of hyperglycemia and diabetes in patients taking Zyprexa. FDA has asked all manufacturers of atypical antipsychotic medications, including Lilly, to add this Warning statement to labeling.Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
Data sources include Micromedex™ (updated May 16th, 2013), Cerner Multum™ (updated May 20th, 2013), Wolters Kluwer™ (updated Apr 30th, 2013) and others. To view content sources and attributions, refer to our editorial policy.
Copyright © 2000-2013 Drugs.com. All rights reserved.
We comply with the HONcode standard for trustworthy health information.
Verify here
